Obermatt
See Similar Stocks →

Sumitomo Dainippon Pharma

TYO:4506 · JP3495000006
PharmaceuticalsLarge

360

79
EV / EBIT89
Price / Owner Earnings74
Owner Earnings Yield98
Dividend Yield71
Price/Sales70
EV / Gross Profit83
Price/Book54
Return on Capital49
Cash Return on Capital90
Return on Equity96
EBIT Margin24
Gross Profitability34
Cash Conversion13
Accruals54
Owner Earnings Margin91
Sales growth89
Profit Growth28
Long-Term EPS Growth25
Owner Earnings Growth88
Reinvestment22
Price momentum98
Debt load28
Refinancing10
Debt Payback27
Liquidity54
Analyst ratings18
Opinion Changes87
Price Target Upside78
Market mood39
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Sumitomo Dainippon Pharma generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryJapan
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeTSE
Founded1897
Employees132
Websitesumitomo-pharma.co.jp
ISINJP3495000006
Last UpdateApr 2, 2026
Indices
Nikkei 225 (Japan)
Themes
DiabetesStem Cell TherapyUrologyNeurologyWomen's HealthCentral Nervous SystemEndocrinologyOncologyPsychiatryBiotechnologyHealth CareHealth DiagnosticsPharmaceutical

Description

Sumitomo Pharma Co., Ltd. (Sumitomo Pharma) is a diversified global pharmaceutical company that engages in the research, development, manufacturing, and marketing of pharmaceuticals. The company focuses on two main business areas: ethical pharmaceuti…

Analysis

Bargain bin

Sumitomo Pharma Co., Ltd. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is attractive. You pay 4.7× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -14% yearly growth; analysts expect 3%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 18/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
52
2023202420252026

All-time high

52

Jun 2026

All-time low

4

Jan 2024

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
70
91
100
95
Price/Earnings
96
33
97
93
Price/Book
54
31
97
89
Dividend Yield
71
1
1
68
Value (overall)
96
30
66
97

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sumitomo Dainippon Pharma with its peers
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Ono Pharmaceutical
TYO:4528
87
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Chong Kun Dang
KSC:185750
55
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aprogen Biologics
KSC:003060
10
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Dong-A Socio
KSC:000640
85
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Japan Tobacco
TYO:2914
96
CountryJapan
IndustryTobacco
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →